newsfilter
← Latest News
GlobeNewswire·

Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter of 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in the fourth quarter of 2024 Obesity